CPI and Abingdon Health sign MoU to bridge the gap between MedTech innovation and market

A scientist looking through a microscope.
A scientist looking through a microscope.
A scientist looking through a microscope.

CPI has signed a Memorandum of Understanding (MoU) with Abingdon Health plc, a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and MedTech to explore opportunities for collaboration across the MedTech sector.

The relationship will create a clear route for diagnostics innovators to progress from early-stage technology development through product validation, regulatory approval, scale-up manufacturing and commercial deployment.  

The agreement brings together CPI’s expertise in developing complex MedTech technologies, including diagnostics, biosensors, connected health devices and advanced medical products, with Abingdon Health’s established contract development and manufacturing capabilities, performance evaluation, regulatory expertise, clinical trial management and commercialisation support.  

Following Abingdon's recent expansion into the US, the MoU will further the organisation's ability to respond to growing demand for innovative development and manufacture of rapidly deployable diagnostic testing solutions in the market. 

By aligning their complementary capabilities, the organisations aim to support MedTech companies in overcoming one of the sector’s most significant challenges: bridging the gap between breakthrough innovation and successful commercial adoption. 

A clinician inspecting a breast scan on a screen.

Accelerating MedTech innovation: From discovery to impact

Share

Anthony Celli, Commercial Director of CPI, said: 

The UK and US are home to world-class MedTech innovation, but many developers face challenges when moving from technology development to commercial manufacturing and regulatory approval. By combining CPI’s expertise in technology development and scale-up with Abingdon Health’s proven capabilities in manufacturing, validation and regulatory support, we can provide innovators with a clearer pathway to market and help accelerate the delivery of transformative healthcare technologies.

Anthony Celli

Commercial Director, CPI

Chris Hand, Executive Chairman of Abingdon Health, commented: 

Abingdon Health has built an integrated offering that helps MedTech and diagnostic innovators navigate the critical stages between development and commercialisation. Through this partnership with CPI, we can engage with promising technologies earlier in their journey and provide a seamless route to product verification, regulatory approval and scalable manufacture. Together, we are creating a compelling proposition for companies looking to bring innovative healthcare solutions to market.

Chris Hand

Executive Chairman, Abingdon Health

Under the MoU, CPI and Abingdon Health will work together to identify opportunities where CPI can support innovators during the early phases of technology development, proof of concept, prototyping and process development. Programmes can then be transitioned to Abingdon Health for product verification, validation, regulatory support and scalable manufacturing. Both organisations hold ISO 13485-certified quality systems which will further simplify and accelerate any transfer.  

Abingdon Health provides integrated development and manufacturing services spanning assay and device development, scale-up manufacturing, quality assurance, performance evaluation and clinical trial management, regulatory consultancy and market access support across a range of diagnostic and MedTech applications. The company operates under an established quality management system and supports customers through development, regulatory approval and commercial manufacture. 

Supporting innovation from concept to commercial impact 

The organisations expect the collaboration to create opportunities across a broad range of MedTech applications, including in vitro diagnostics, biosensors, wearable technologies, digital health solutions and next-generation medical devices. By combining CPI’s product development and manufacturing innovation expertise with Abingdon Health’s commercialisation capabilities, the partnership will help innovators reduce risk, shorten development timelines and improve their path to market readiness.  

MedTech device showing an Xray image of a human head.

Explore our MedTech capabilities

Share